Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30926986 | 1.00 | KDM4E (0.31) | KDM4EALDH1A1CYP2C9TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL17560231 | 0.97 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL272458 | 0.97 | — | — | |
| SCHEMBL15366209 | 0.97 | — | — | |
| Bromide SCHEMBL7941597 | 0.94 | KDM4E (0.31) | KDM4EALDH1A1CYP2C9TSHRCYP2C19 | |
| Methyl Alcohol SCHEMBL26106863 | 0.92 | KDM4E (0.36) | KDM4EALDH1A1CYP2C9TSHRCYP2C19 | |
| SCHEMBL23505786 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL2257363 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL21121551 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL18386 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| US-20250214998-A1 | CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-07-03 | — | — | US | disclosed |
| US-12275732-B2 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2025-04-15 | — | — | US | disclosed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-115768769-B | Tetrahydroisoquinoline compound and application thereof | 南京再明医药有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2024-10-17 | — | — | US | disclosed |
| WO-2024183629-A1 | USE OF 3CLPRO INHIBITOR IN PREPARATION OF DRUG FOR TREATING DISEASES CAUSED BY FELINE CORONAVIRUS | 齐鲁动物保健品有限公司 | 2024-09-12 | — | — | WO | disclosed |
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | US | disclosed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | disclosed |
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112848-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-1546147-A1 | MORPHOLINE-BRIDGED INDAZOLE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004031186-A1 | MORPHOLINE-BRIDGED INDAZOLE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1406908-A1 | MORPHOLINE-BRIDGED PYRAZOLOPYRIDINE DERIVATIVES | Bayer HealthCare AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004503-A1 | MORPHOLINE-BRIDGED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | OPRM1, OPRK1, OPRD1 | KDM4E 2881/4885ALDH1A1 1430/4885CYP2C9 695/4885 |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | C1R, C3AR1, CXCR3 | KDM4E 3943/4885ALDH1A1 3993/4885CYP2C9 166/4885 |
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | POLR1C, CCR1, COL1A1 | KDM4E 3261/4885ALDH1A1 1855/4885CYP2C9 1784/4885 |
| US-20250214998-A1 | CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF | CHRNA7, CHRNA5, CHRNA1 | KDM4E 3575/4885ALDH1A1 836/4885CYP2C9 1995/4885 |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM2, CHRM1, C1R | KDM4E 4124/4885ALDH1A1 3642/4885CYP2C9 160/4885 |
| US-12275732-B2 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | KDM4E 3556/4885ALDH1A1 832/4885CYP2C9 1938/4885 |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | GUCY1B2, COG4, GUCY1A2 | KDM4E 1499/4885ALDH1A1 3891/4885CYP2C9 4352/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | KDM4E 3977/4885ALDH1A1 3917/4885CYP2C9 667/4885 |
| US-11918586-B2 | Treatment of skin lesions | C1R, C3AR1, CXCR3 | KDM4E 3943/4885ALDH1A1 3993/4885CYP2C9 166/4885 |
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | KDM4E 895/4885ALDH1A1 1593/4885CYP2C9 1963/4885 |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | GUCY1A1, PDE1A, PDE3B | KDM4E 4394/4885ALDH1A1 1862/4885CYP2C9 2943/4885 |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KDM4E 3736/4885ALDH1A1 163/4885CYP2C9 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.